UBS Adjusts Edwards Lifesciences Price Target to $92 From $84, Maintains Neutral Rating
UBS Adjusts Edwards Lifesciences Price Target to $92 From $84, Maintains Neutral Rating
瑞银将爱德华兹生命科学的目标股价从84美元调整至92美元，维持中性评级
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册